Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
povorcitinib
- Development stage
- Phase 3
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Povorcitinib is an orally administered small molecule that acts as a selective Janus kinase 1 (JAK1) inhibitor. It is being developed primarily for the treatment of moderate to severe hidradenitis suppurativa (HS), but is also under investigation for prurigo nodularis, nonsegmental vitiligo, chronic spontaneous urticaria (CSU), and asthma. Povorcitinib works by selectively inhibiting JAK1, a key enzyme involved in inflammatory and immune signaling pathways implicated in these diseases. Clinical trials have demonstrated significant efficacy in reducing disease activity and symptoms in HS patients with a favorable safety profile. The drug was developed by Incyte.
- Other names
- povorcitinib
02
Targets
Beyond the preview
Go deeper on povorcitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on povorcitinib.